These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27207777)

  • 1. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
    Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
    Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK11
    Du Y; Yan D; Yuan Y; Xu J; Wang S; Yang Z; Cheng W; Tian X; Kan Q
    Cell Cycle; 2019 Feb; 18(4):452-466. PubMed ID: 30722725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.
    Jia B; Choy E; Cote G; Harmon D; Ye S; Kan Q; Mankin H; Hornicek F; Duan Z
    Cancer Lett; 2014 Jan; 342(1):104-12. PubMed ID: 24007862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.
    Duan Z; Zhang J; Choy E; Harmon D; Liu X; Nielsen P; Mankin H; Gray NS; Hornicek FJ
    Clin Cancer Res; 2012 Sep; 18(17):4580-8. PubMed ID: 22791884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
    Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
    Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
    Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
    Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
    Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
    Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Yang H; Shu Z; Jiang Y; Mao W; Pang L; Redwood A; Jeter-Jones SL; Jennings NB; Ornelas A; Zhou J; Rodriguez-Aguayo C; Bartholomeusz G; Iles LR; Zacharias NM; Millward SW; Lopez-Berestein G; Le XF; Ahmed AA; Piwnica-Worms H; Sood AK; Bast RC; Lu Z
    Clin Cancer Res; 2019 Sep; 25(18):5702-5716. PubMed ID: 31391192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.